Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
about
Clopidogrel and proton pump inhibitors--where do we stand in 2012?Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Antiplatelet drug interactions with proton pump inhibitorsA multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersGenotype and allele frequency of CYP2C19*17 in a healthy Iranian populationPopulation pharmacokinetic analysis of axitinib in healthy volunteers.The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.A benefit-risk assessment of the use of proton pump inhibitors in the elderly.Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substratesGenetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.Pharmacare: Are we getting the right medicines?Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population.Dealing with uncertainty in the treatment of Helicobacter pylori.Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Pilot study for the characterization of pharmacogenetically relevant CYP2D6, CYP2C19 and ABCB1 gene polymorphisms in the Hungarian population.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.
P2860
Q26825728-AF7AE00F-D8AB-4B7A-B591-694E4BC7D907Q33692784-AAD0A60F-CCB0-47EE-AB06-59B076993831Q33891049-7F5E9D90-1E75-4800-A771-98CE329C9542Q33948811-10BFA31F-A554-4573-BE70-563D7A5F6036Q35308159-9CAB2094-E2AE-4DAC-BDCA-A9813DA3CC41Q36164941-9FFCF843-ACD2-49DE-AF06-517A293372D6Q36469405-AEF5297F-1FF8-4E78-BE25-166C16CC348CQ37635202-B8D6EA30-9433-4FCD-B36B-8290A094DB29Q38117182-4D0C44EF-2463-434E-8AD8-547D834BDD1EQ38196383-3E1AA735-A3EE-4C48-9D88-880C7432AFE4Q38578674-0647600E-725F-49D7-824D-79F6189EC7FCQ38876344-8AA45968-675F-4524-9E21-8112C63CDD7EQ40389903-1FC20CCB-CE4C-4878-BE33-F96FB4E27110Q40569531-EA2007DC-60BB-4354-A776-7323708CA060Q40772216-D0AB1561-6901-4A0F-8CD9-CAB5C4B0E7DEQ41532194-112F6028-DD94-46E8-BB3D-72BBFB67A855Q41706384-21925E31-02B5-4BE6-BA4C-0E822E09ADBFQ41986948-AE78D24A-8445-4870-B191-A15DD2B2F8C2Q43071574-B119D378-88C7-4ECF-BA28-C2F5EB2A36A7Q44093566-EE57C134-78CB-4CE2-A309-B78FC49826E6Q45179286-74B01143-8C83-4A45-8738-526D13249656Q45916609-6B3B17F9-13C8-4B97-A205-A964C8BE6E48Q47404372-1B157EA6-0EC5-4DF7-9491-8E2057773302Q48170836-0CA7ABA0-4F92-4443-8AFF-944F7B049E4AQ49997264-D5B240B8-8595-4468-8D44-56E8FDAAE6FFQ51653421-4B102429-2F06-4132-B570-17AAEC04B7F0Q52330458-EDCB4F35-A51D-4DE0-A880-F017019C1EF6Q53665185-F2144B5F-19EF-4B04-AEDF-DB832B1DFB9FQ54355038-E8D6103F-5FAD-4BF7-8E63-9C2B1E47B4A2Q55280841-A6AC9B25-5F1F-4309-9046-702873D68B8D
P2860
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@ast
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@en
type
label
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@ast
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@en
prefLabel
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@ast
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@en
P2093
P2860
P1476
Effect of CYP2C19*2 and *17 mu ...... pump inhibitors in Caucasians.
@en
P2093
Daan J Touw
Nicole G Hunfeld
Paul F Franck
Paul G Mulder
Ron A Mathot
Ron H van Schaik
William P Geus
P2860
P304
P356
10.1111/J.1365-2125.2007.03094.X
P407
P577
2008-01-30T00:00:00Z